drugset / Trial / NCT00106847

A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis

NCT00106847

Phase 3 Completed 683 enrolled Centocor, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

Timeline

Start
2003-01
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 3 mg/kg
Subject Infliximab Monoclonal antibody 5 mg/kg

Indications